Navigation Links
Immune therapy for advanced bladder cancer yields promising results
Date:5/31/2014

New Haven, Conn. A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.

The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The patients in the study were treated with MPDL3280A, a drug being developed by Genentech, a member of the Roche group.

At six weeks, the objective response rate (ORR) was 43%; at 12 weeks, the ORR was 52% in patients with PD-L1-positive tumors. A complete response one showing no evidence of tumors was seen in 7% of PD-L1 patients. In patients with PD-L1-negative tumors, the response rate was 11%.

The results in advanced bladder cancer patients "point to a new era in cancer treatment for a disease that has not seen a major advancement since the introduction of cisplatin-based combination therapy in the 1980s," said the study's senior author Daniel P. Petrylak, M.D., professor of medicine and urology at Yale Cancer Center and Yale School of Medicine. "We look forward to opening the phase II trial at Yale in June to confirm these findings."

Yale Cancer Center enrolled 12 of the 68 patients on the trial at Smilow Cancer Hospital at Yale-New Haven.


'/>"/>

Contact: Vicky Agnew
vicky.agnew@yale.edu
843-697-6208
Yale University
Source:Eurekalert

Page: 1

Related medicine news :

1. How does the immune system fight off threats to the brain? New research yields fresh insight
2. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
3. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
4. Rutgers team discovers novel approach to stimulate immune cells
5. Scientists study serious immune malfunction
6. Babies susceptibility to colds linked to immune response at birth
7. Reactions to HIV drug have autoimmune cause, reports AIDS journal
8. First study to suggest that the immune system may protect against Alzheimers changes in humans
9. Belly Membrane May Regulate Immune System, Mouse Study Finds
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Researchers reveal crucial immune fighter role of the STING protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board ... of Integrative Medicine and available for application on Saturday, May 27, 2017, following ... in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... Perry, GA (PRWEB) , ... March 28, 2017 , ... ... headquarters to Marshallville, Georgia, in early March. , The seed processing plant opened in ... the location since 2016. The new office allows opportunity for transition of Patten Seed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common and ... Advanced Dermatology has a lot to offer to the discussion of dealing with ... news is that there are many home remedies that can help remove the oily shine ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Md. , March 27, 2017  ImMAGE Biotherapeutics ... its immunotherapy successfully passed early toxicology and efficacy studies. ... system to target a specific protein, MAGE A, in ... negative breast cancer. After 4 weeks ... able to show very little toxicity in a full ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology: